RTSN · Retension Pharmaceuticals, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-10-13 | Keller Eric L. |
Director, Chief Executive Officer |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Common Stock
|
9,662 |
| 2026-10-13 | Keller Eric L. |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Series A Convertible Preferred Stock
|
9,662 |
| 2026-10-13 | Keller Eric L. |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on August 14, 2027, with the remaining stock options vesting in 36 monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Stock Option (right to buy)
|
255,174 |
| 2026-10-13 | Bisson Sabine |
Chief Operating Officer |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Common Stock
|
1,611 |
| 2026-10-13 | Sweetnam Paul |
Chief Scientific Officer |
Other↓
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Series A Convertible Preferred Stock
|
4,026 |
| 2026-10-13 | BERENDT MICHAEL J |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Common Stock
|
4,026 |
| 2026-10-13 | Olds Donald |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Common Stock
|
5,637 |
| 2026-10-13 | Keller Eric L. |
Director, Chief Executive Officer |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Common Stock
|
31,368 |
| 2026-10-13 | Sweetnam Paul |
Chief Scientific Officer |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Common Stock
|
4,026 |
| 2026-10-13 | Bisson Sabine |
Chief Operating Officer |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Common Stock
|
2,504 |
| 2026-10-13 | Sweetnam Paul |
Chief Scientific Officer |
Other↓
Filing footnotes — Series B Convertible Preferred Stock (Indirect)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Series B Convertible Preferred Stock
(I)
|
2,640 |
| 2026-10-13 | Keller Eric L. |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Series B Convertible Preferred Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Series B Convertible Preferred Stock
|
31,368 |
| 2026-10-13 | BERENDT MICHAEL J |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Common Stock
|
2,640 |
| 2026-10-13 | BERGER FRANKLIN M |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Common Stock
|
12,517 |
| 2026-10-13 | Bisson Sabine |
Chief Operating Officer |
Other↓
Filing footnotes — Series B Convertible Preferred Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Series B Convertible Preferred Stock
|
2,504 |
| 2026-10-13 | Olds Donald |
Director |
Other↓
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Series A Convertible Preferred Stock
|
5,637 |
| 2026-10-13 | BERENDT MICHAEL J |
Director |
Other↓
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Series A Convertible Preferred Stock
|
4,026 |
| 2026-10-13 | BERGER FRANKLIN M |
Director |
Buy↑
|
Common Stock
(I)
|
10,000 |
| 2026-10-13 | Keller Eric L. |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
20,800 |
| 2026-10-13 | BERENDT MICHAEL J |
Director |
Other↓
Filing footnotes — Series B Convertible Preferred Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Series B Convertible Preferred Stock
|
2,640 |
| 2026-10-13 | Bisson Sabine |
Chief Operating Officer |
Other↓
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had no expiration date. |
Series A Convertible Preferred Stock
|
1,611 |
| 2026-10-13 | Sweetnam Paul |
Chief Scientific Officer |
Other↑
Filing footnotes — Common Stock (Indirect)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Common Stock
(I)
|
2,640 |
| 2026-10-13 | BERGER FRANKLIN M |
Director |
Other↓
Filing footnotes — Series B Convertible Preferred Stock (Direct)
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date. |
Series B Convertible Preferred Stock
|
12,517 |
| 2026-10-13 | Cheruvu Pavan |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Stock Option (right to buy)
|
5,636 |
| 2026-10-08 | Olds Donald |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Stock Option (right to buy)
|
5,636 |
| 2026-10-08 | BERGER FRANKLIN M |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Stock Option (right to buy)
|
5,636 |
| 2026-10-08 | BERENDT MICHAEL J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Option award granted pursuant to the Issuer's 2026 Equity Incentive Plan. Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 12 quarterly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Stock Option (right to buy)
|
5,636 |